Front-line Indian firms have thrown down the gauntlet to Boehringer Ingelheim GmbH with the launch on the domestic market of their cut-price versions of nintedanib for idiopathic pulmonary fibrosis (IPF), a chronic and ultimately fatal disease characterized by a decline in lung function.
First off the block appears to have been Sun Pharmaceutical Industries Ltd
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?